J
James A. Torchia
Researcher at Harvard University
Publications - 17
Citations - 1640
James A. Torchia is an academic researcher from Harvard University. The author has contributed to research in topics: Antibody & Immune system. The author has an hindex of 10, co-authored 15 publications receiving 1389 citations. Previous affiliations of James A. Torchia include University of California, San Francisco & Carnegie Mellon University.
Papers
More filters
Journal ArticleDOI
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua Brody,Weiyun Z. Ai,Debra K. Czerwinski,James A. Torchia,Mia A. Levy,Ranjana H. Advani,Youn H. Kim,Richard T. Hoppe,Susan J. Knox,Lewis K. Shin,Irene Wapnir,Robert Tibshirani,Ronald Levy +12 more
TL;DR: In situ tumor vaccination with a TLR9 agonist induces systemic antilymphoma clinical responses and is clinically feasible and does not require the production of a customized vaccine product.
Journal ArticleDOI
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurélien Marabelle,Holbrook E Kohrt,Idit Sagiv-Barfi,Bahareh Ajami,Robert C. Axtell,Gang Zhou,Ranjani Rajapaksa,Michael R. Green,James A. Torchia,Joshua Brody,Richard Luong,Michael Rosenblum,Lawrence Steinman,Hyam I. Levitsky,Victor Tse,Ronald Levy +15 more
TL;DR: It is proposed that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.
Journal ArticleDOI
TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1.
Qisheng Peng,Qisheng Peng,Shikha Malhotra,James A. Torchia,William G. Kerr,K. Mark Coggeshall,Mary Beth Humphrey,Mary Beth Humphrey +7 more
TL;DR: A previously uncharacterized interaction of SHIP1 with DAP12 is demonstrated that functionally limits TREM2- and DAP 12-dependent signaling and a mechanism through which SHIP 1 regulates key ITAM-containing receptors by directly blocking the binding and activation of PI3K is identified.
Journal ArticleDOI
TREM2, a DAP12-Associated Receptor, Regulates Osteoclast Differentiation and Function†
Mary Beth Humphrey,Michael R. Daws,Steven C. Spusta,Eréne C. Niemi,James A. Torchia,Lewis L. Lanier,William E. Seaman,Mary C. Nakamura +7 more
TL;DR: The role of TREM2 is examined in mouse OC development and function, including migration and resorption in vitro, providing new evidence that TREM 2 regulates OC function independent of its effects on multinucleated OC differentiation.
Journal ArticleDOI
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Roch Houot,Matthew J. Goldstein,Holbrook E Kohrt,June Helen Myklebust,Ash A. Alizadeh,Jack T. Lin,Jonathan M. Irish,James A. Torchia,Arne Kolstad,Lieping Chen,Ronald Levy +10 more
TL;DR: It is demonstrated that anti-CD137 therapy has potent antilymphoma activity in vivo and could be further enhanced by depletion of regulatory T cell (T(regs), which support the evaluation of anti- CD137 therapy in clinical trials for patients with lymphoma.